Cognition Therapeutics Inc

Home
United States
Purchase, NY
Cognition Therapeutics Inc

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Cognition Therapeutics Inc, Biotechnology company, 2500 Westchester Avenue, Purchase, NY.

09/18/2026

This year’s is focused on the importance of a timely diagnosis. A diagnosis can open the door to resources, support, and therapeutic options. .

New diagnostics and disease-modifying treatments for and related dementias are available, and more are being developed by biotechnology and pharmaceutical companies all over the world. An early and accurate diagnosis can tell you what form of you have, which in turn can help your neurologist tailor a treatment plan for you. Learn more: https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia

09/10/2026

According to Alzheimer's Disease International, 35% of carer partners around the world say that they have hidden a loved one's diagnosis from family. https://www.alzint.org/about/dementia-facts-figures/

Let's take a moment during to educate ourselves and combat the stigma that surrounds and related dementias. If you or a loved one is living with dementia, there are resources at the Alzheimer's Association and U.S. Department of Veterans Affairs to help you tell family and friends.

09/03/2026

September is World Alzheimer’s Month - an internationally coordinated campaign to raise awareness and reduce the stigma of dementias like disease, with Lewy bodies, and others. Symptoms of memory loss, agitation, are common yet seldom discussed.

The focus of this year's is to reduce stigma, increase education, and empower people to discuss their symptoms with their care partners and physicians so everyone can receive an accurate and timely diagnosis.

Take a moment to learn more about dementia today. https://www.alzint.org/about/

07/28/2026

It's time to rethink neurodegenerative disease.

For decades, diseases like , , and have been diagnosed based on clinical symptoms. However, emerging evidence suggests these aren't discrete disorders but rather points on a complex and interconnected continuum.

In a new article for Neurology Advisor, our chief medical officer, Dr. Anthony Caggiano, MD, PhD, explores the shift towards a "biology-first" approach.

Read the full article to learn more about the future of neurodegenerative care: https://www.neurologyadvisor.com/features/neurodegenerative-disease-myth-of-pure-pathology/

06/24/2026

$CGTX received written feedback from the U.S. following their meeting in May. Read the press release here: https://buff.ly/8k9prmh

The FDA agreed that associated with with Lewy bodies (DLB) could be an approvable outcome. The agency also reached alignment with the Company on key aspects of a pivotal trial for , which is expected to begin in mid-2027.

06/11/2026

$CGTX CEO, will join H.C. Wainwright's Dr. Ram Selvaraju for a virtual fireside chat during their Neuro Perspectives Expert Summit. The virtual fireside will be available on demand beginning at 7:00am ET on June 15th. Find a link to the live and archived presentation on the Cognition Therapeutics IR webpage: https://ir.cogrx.com/events/

06/04/2026

$CGTX CEO, Lisa Ricciardi, will present at 1:25 p.m. ET today at the 2026 Global Healthcare Conference, which is being held at the Marriott Marquis in New York City. Find a link to the live and archived presentation on the Cognition Therapeutics IR webpage: https://ir.cogrx.com/events/

01/27/2026

$CGTX conducted a Type C meeting with the to review plans for the proposed Phase 2b study of zervimesine in with Lewy bodies (DLB). : https://tinyurl.com/23vts78p

01/09/2026

It's the Friday before . Slide decks are polished. Travel plans made. Looking forward to seeing old colleagues and making new connections next week at the and Longwood Healthcare Leaders meetings.

01/07/2026

$CGTX announced that the manuscript, “Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)” has been published in the journal, Alzheimer's & Dementia. The open-access article can be found here: https://tinyurl.com/26vvrqes

Cognition's chief medical officer, Dr. Caggiano, explained, "Zervimesine was shown to have a favorable impact on behavioral, cognitive, functional, and movement domains, many of which are core clinical features of DLB. There are currently no approved disease-modifying treatments for DLB, highlighting the unmet need for novel therapies.”

Address

2500 Westchester Avenue
Purchase, NY
10577

Website

https://www.cogrx.com/

Alerts

Be the first to know and let us send you an email when Cognition Therapeutics Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cognition Therapeutics Inc:

Want your business to be the top-listed business in Purchase?